Intranasal Mesenchymal Stromal Cells for Perinatal Arterial Stroke: Promising Safety and Improved Neurodevelopment at Two Years
The PASSIoN study shows that intranasally administered allogeneic mesenchymal stromal cells in neonates with perinatal arterial ischemic stroke are safe up to two years and suggest better motor outcomes compared to untreated cohorts.